About us

Our name, Enara Bio®, is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in discovering and validating Dark Antigens®, a rich source of novel cancer targets derived from areas of the genome previously considered to be ‘dark’ or non-coding. Through our proprietary EnTiCE® platform, we are developing first-in-class bispecific T-cell engagers against novel targets to improve treatment outcomes for broad populations of cancer patients.

Enara Bio is backed by prominent life science investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Enara Bio Our Story Poster

Leadership Team

Kevin Pojasek
President and CEO
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer and Head of Translational Science
Joseph Dukes
Chief Scientific Officer
Stacey Davis
Chief Business Officer and Chief Financial Officer

Board of Directors

Scientific Advisors & Founders

Investors

Clive Wood

Director

Clive Wood brings over three decades of scientific leadership and drug discovery expertise, with a track record of advancing innovative therapeutics across oncology and inflammation. Currently a Venture Partner at OrbiMed, Clive previously served as Global Head of Discovery Research at Boehringer Ingelheim, where he led a team that delivered a highly productive portfolio across diverse disease areas and modalities. Prior to his time at Boehringer Ingelheim, Clive served as Head, Global Biologics at Bayer HealthCare, Chief Scientific Officer at Dyax Corp, and Senior Scientist at Genetics Institute, Inc. Clive’s personal scientific accomplishments have focused on antibody therapeutics and cytokines in oncology and inflammation, including his discovery of the PD-1: PD-L1/PD-L2 pathway. He is a co-inventor of the core patents that relate to the treatment of cancer with antibodies against PD-1 and its ligands. Clive received B.Sc. and Ph.D. degrees from Imperial College London.